Early clinical safety and efficacy data for the IDO1 inhibitor (epacadostat) in combination with anti-PD-1 (pembrolizumab) were promising for the treatment of various advanced cancers in a phase I/II study (e.g., melanoma, RCC, and NSCLC) (172). This evidence concerns the gene IDO1 and cancer.